Reeling from PhII flop, CytomX lays off 40% as execs go back to drawing board, seek new deals

Just days after putting a lead drug on the backburner in the wake of a Phase II flop, CytomX has settled on a makeover plan.

The South San Francisco biotech is laying off around 40% of its staffers as part of a revamp intended to prioritize internal work on its...

Click to view original post